SUTENT Offers Experience in 1^st-Line mRCC

• SUTENT has more than 5 years' experience in advanced RCC since its FDA approval
• In the United States, SUTENT is the most prescribed among oral medications approved for the treatment of advanced RCC^*
• More than 100,000 patients worldwide have been treated with SUTENT across indications^1†
• SUTENT has had an NCCN category 1 recommendation for 1^st-line treatment of clear-cell mRCC since 2008²

Access SUTENT efficacy data in the treatment of mRCC

^*Based on IMS/NPA Plus and ImpactRx data, September 2010 to August 2011. IMS/NPA Plus does not collect actual patient diagnosis information, including diagnosis of advanced RCC.¹

^†Including patients with any diagnosis, as calculated by the SUTENT Worldwide Patient Exposure. Estimate from February 2006 to September 2010.¹

All references to the NCCN are used with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^™) for Soft Tissue Sarcoma V.2.2011. © 2011 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines^™ may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK^®, NCCN^®, NCCN GUIDELINES^™, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

Follow-up Results for SUTENT in mRCC

An analysis of progression-free survival (PFS) and overall survival (OS) results from a phase 3 trial of sunitinib versus interferon alfa (IFN) as 1^st-line treatment of metastatic renal cell carcinoma (RCC).

Access the reprint now